Literature DB >> 16200268

[Cardiac papillary fibroelastoma. Experience of an institution].

Suzelle F de M Oliveira1, Ricardo Ribeiro Dias, Fábio Fernandes, Noedir A G Stolf, Charles Mady, Sérgio Almeida de Oliveira.   

Abstract

Primary intracardiac tumors are rare, with prevalence between 0.0017% and 0.19% from non-selected autopsy studies. Approximately 75% are benign and almost half of them are myxomas. The remaining tumors are divided among rhabdomyomas, lipomas and fibroelastomas. Myxomas are the most common intracardiac tumors in adult age and rhabdomyomas the most common among pediatric population. Papillary fibroelastoma (PFE) is a relative rare benign heart tumor, corresponding to approximately 8% of intracardiac tumors. They most commonly manifested in cardiac valves. In the past, they either consisted of necropsy findings or were found in surgical procedures at random. In vivo diagnosis was sporadic. With the improvement of echocardiography techniques, PFE has been more frequently diagnosed. They are usually described as a movable, pedunculate, well-delimited mass and with predilection for valve endocardium. Therapeutic proposal, when they are pedunculate, is surgical resection, preventing cerebral, pulmonary, coronary or peripheral embolic phenomena. Five cases diagnosed in our institution, in the period from August 1995 to June 2004, will be presented.

Entities:  

Mesh:

Year:  2005        PMID: 16200268     DOI: 10.1590/s0066-782x2005001600010

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


  1 in total

1.  Mitral Valve Papillary Fibroelastoma as the Cause of Ischemic Stroke in a Young Patient: A Case Report.

Authors:  Milena Miranda Vasconcelos; Caroline Ferreira da Silva Mazeto Pupo da Silveira; Marcello Laneza Felício; Marcelo Padovani de Toledo Moraes; Renato Teixeira; Stella de Angelis Trivellato; Gabriel Pinheiro Modolo; Rodrigo Bazan; Silméia Garcia Zanati Bazan
Journal:  Am J Case Rep       Date:  2021-03-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.